A phase 1 clinical trial evaluating SYN002 for the treatment of cytomegalovirus (CMV)
Latest Information Update: 14 Jun 2022
At a glance
- Drugs SYN 002 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
Most Recent Events
- 14 Jun 2022 New trial record
- 08 Jun 2022 According to a Synklino media release, company plans to submit clinical trial application in the first half of 2023.